Body weight increment in patients treated with infliximab for plaque psoriasis
- 23 May 2012
- journal article
- research article
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 27 (2) , e186-e190
Abstract
Background Psoriasis is frequently associated with overweight and obesity. Anti‐TNF‐α therapies are effective in the treatment of psoriasis. TNF‐α is highly involved in body weight regulation.Objective Our objective was to evaluate the increase in weight throughout the treatment with infliximab and the association of weight gain with the body mass index (BMI).Methods Thirty‐five patients affected with severe plaque psoriasis receiving infliximab were included. A control group consisted of 16 patients affected with severe plaque psoriasis and treated with cyclosporine, methotrexate, or acitretin. Assessment of PASI score, body weight and BMI were performed at a 1 and 3‐year follow‐up.Results We observed a body weight increment of 2.5 ± 4.4 kg (mean ± SD) (i.e. + 3.6% of baseline) and 0.1 ± 5 kg (i.e. + 1.2%) in patients treated with infliximab and the control group, respectively (P = 0.046), after 1 year of treatment. After 3 years of infliximab administration, weight gain was 4.8 ± 5 kg (n = 16) (i.e. + 6%) (P = 0.005). Moreover, as classified by BMI, normal weight patients experienced a 4 ± 3.7 kg weight gain (i.e. + 6%) whereas overweight and obese patients had gained 1.3 ± 4.8 kg (i.e. + 1.2%) (P = 0.039) after 1 year of anti‐TNF‐α therapy. Percentual changes in body weight were larger in normal weight patients at baseline than in overweight/obese counterparts (P = 0.0149).Conclusion All patients, including normal weight patients, should receive a dietary intervention.Keywords
This publication has 21 references indexed in Scilit:
- The Risk of Stroke in Patients with PsoriasisJournal of Investigative Dermatology, 2009
- Impact of Body Mass Index and Obesity on Clinical Response to Systemic Treatment for PsoriasisDermatology, 2008
- Effect of anti-tumor necrosis factor-α therapies on body mass index in patients with psoriasisPharmacological Research, 2008
- The Risk of Mortality in Patients With PsoriasisArchives of Dermatology, 2007
- Anti–tumour necrosis factor‐α therapy increases body weight in patients with chronic plaque psoriasis: a retrospective cohort studyJournal of the European Academy of Dermatology and Venereology, 2007
- Prevalence of cardiovascular risk factors in patients with psoriasisJournal of the American Academy of Dermatology, 2006
- Prevalence and Treatment of Psoriasis in the United KingdomArchives of Dermatology, 2005
- Body weight, body composition, and bone turnover changes in patients with spondyloarthropathy receiving anti-tumour necrosis factor α treatmentAnnals of the Rheumatic Diseases, 2005
- TNF‐α increases ubiquitin‐conjugating activity in skeletal muscle by up‐regulating UbcH2/E2 20kThe FASEB Journal, 2003
- Effect of Short-Term Fasting on Free and Bound Leptin Concentrations in Lean and Obese WomenThe Journal of Clinical Endocrinology & Metabolism, 2001